Zantac Injection Returns to Market

Covis Pharmaceuticals announced that Zantac (ranitidine HCl) Injection 25mg/mL is once again available for therapeutic use. Zantac Injection is a histamine H2-receptor antagonist indicated for the treatment of hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.

Zantac Injection is available from Covis in 2mL, 6mL and 40mL vials. The company expects to make available Zantac Injection 50mg premixed bags by the summer.

For more information call (919) 535-3049 or visit www.covispharma.com.